Clinical trials: Liver Function Failure
Hepatic Encephalopathy, Acute-On-Chronic Liver Failure
Role of Bilirubin Molecular Species in Hepatic Encephalopathy and Acute-on-chronic Liver Failure
It has been identified that impaired liver function, as occurs in patients with liver cirrhosis, prevents proper conjugation of glucuronic acid with bilirubin; as a result, unconjugated bilirubin accumulates in the blood, and…
- Trial name
- NCT05566548
- Testing
- Liquid Chromatography-Mass Spectrometry Method to identify bilirubin molecular species
- Where
- Mexico
- Volunteers
- 50 people, healthy volunteers welcome
- Sponsor
- Medica Sur Clinic & Foundation
End Stage Liver Disease
Evaluation of Frailty and Functional Capacity in End-Stage Liver Disease
Development of fibrosis plays a main role in the pathophysiology of liver diseases. The rate of progression in fibrogenesis varies according to the type of underlying liver disease and varies with the environment and host-related…
- Trial name
- NCT04220723
- Testing
- Frailty Assessment, Functional Capacity Assessment
- Where
- Turkey (Türkiye)
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- Hacettepe University
GVHD, Bone Marrow Transplant Failure
α1-antitrypsin (AAT) Levels and Functions in Allogeneic Bone Marrow Transplantation and Throughout Progression Into GVHD
Create a personalized time and context curve of patient circulating α1-antitrypsin (AAT) levels and functions before hematopoietic stem cell transplantation and throughout progression into GVHD. PRIMARY ENDPOINT 1.
- Conditions
- GVHD, Bone Marrow Transplant Failure, Alpha 1-Antitrypsin
- Trial name
- AATGVHD-MARK (NCT03188601)
- Where
- 4 sites in Israel
- Volunteers
- 27 people, healthy volunteers welcome
- Sponsor
- Rambam Health Care Campus
Hepatic Encephalopathy, Cirrhosis
Early Diagnosis and Timely Treatment of Cirrhotic Patients With Minimal Hepatic Encephalopathy (CHESS-NCRCID 2106)
Hepatic encephalopathy (HE) is a common complication of cirrhosis, which seriously damages the life quality of patients. As the disease progresses, 50-80% of patients with cirrhosis develop HE.
- Trial name
- NCT05140837
- Testing
- Psychometric hepatic encephalopathy score & Stroop test, Drug therapy
- Where
- 31 sites in China
- Volunteers
- 10,000 people, healthy volunteers welcome
- Sponsor
- Hepatopancreatobiliary Surgery Institute of Gansu Province
Hepatic Failure, Liver Failure
Cardiox Liver Function Test Pivotal Trial
Performance evaluation of LFT Dye Monitor System using ICG - plasma disappearance rate value (PDR) to assess liver function in normal patients as well as in patients with mild to severe hepatic impairment compared to manual Serum…
- Trial name
- LFT-0002 (NCT02552901)
- Testing
- 0.1 mg/kg ICG Dose, 0.5 mg/kg ICG dose
- Where
- United States
- Volunteers
- healthy volunteers welcome
- Sponsor
- Cardiox Corporation
Acute-On-Chronic Liver Failure, Cirrhosis, Liver
Global Coagulation Assessment in Cirrhosis and ACLF
Background: Patients with cirrhosis and acute-on-chronic liver failure (ACLF) may have bleeding complications which can lead to increased mortality.
- Trial name
- NCT04332484
- Where
- India
- Volunteers
- 142 people, healthy volunteers welcome
- Sponsor
- Post Graduate Institute of Medical Education and Research, Chandigarh
Liver Diseases, Hepatic Encephalopathy
Effects of Branched-Chain Amino Acids on Muscle Ammonia Metabolism in Patients With Cirrhosis and Healthy Subjects
The purpose of this study is to determine whether Branched chain Amino Acids enhances the uptake of ammonia in muscle tissue.
- Conditions
- Liver Diseases, Hepatic Encephalopathy, Hepatic Insufficiency
- Trial name
- NCT00931060
- Testing
- Branched chain amino acids
- Volunteers
- 24 people, healthy volunteers welcome
- Sponsor
- University of Aarhus
Hepatic Failure
Pharmacokinetic Study of Icenticaftor in Participants With Hepatic Impairment
The primary purpose of this study is to evaluate the effect of hepatic impairment on the systemic pharmacokinetics, safety, and tolerability of icenticaftor in participants with varying degrees of hepatic impairment.
- Trial name
- NCT04587622
- Testing
- Icenticaftor
- Where
- 2 sites in United States
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- Novartis Pharmaceuticals
Acute on Chronic Liver Failure, Traditional Chinese Medicine
Study on the Optimal Strategy for Acute-on-chronic Liver Failure With Integrative Treatment
Background: Acute-on-chronic liver failure (ACLF) is a syndrome characterized by acute deterioration in the setting of chronic liver disease associated with high short-term mortality.
- Conditions
- Acute on Chronic Liver Failure, Traditional Chinese Medicine, Hepatitis B
- Trial name
- NCT03577938
- Testing
- Chinese herbal medicine, Control (blank)
- Where
- 15 sites in China
- Volunteers
- 516 people, healthy volunteers welcome
- Sponsor
- Beijing 302 Hospital
Liver Cirrhosis, Acute-On-Chronic Liver Failure
Characterization and Pathogenesis of ACLF
This single-center prospective observational study aims at characterization of pathogenesis of ACLF. There will be three different cohorts investigated with the main endpoint mortality in these groups. 1.
- Conditions
- Liver Cirrhosis, Acute-On-Chronic Liver Failure, Portal Hypertension
- Trial name
- ACLF-I (NCT04975490)
- Where
- Germany
- Volunteers
- 1,000 people, healthy volunteers welcome
- Sponsor
- Johann Wolfgang Goethe University Hospital
Hepatitis, Pharmacology
A Partial Randomized, Single-blind or Open-label, Dose-escalation With Multiple-dose Design Study to Evaluate the Pharmacokinetics of Acetaminophen and Its Toxic Metabolites With Panadol® and SafeTynadol® in Healthy Volunteers
To investigate and compare the possible response of Panadol® and SafeTynadol® formulations in healthy volunteers and the safety in SafeTynadol® dose-limiting hepatotoxicity.
- Trial name
- NCT05563961
- Testing
- Panadol®, SafeTynadol®
- Where
- Taiwan
- Volunteers
- 48 people, healthy volunteers welcome
- Sponsor
- Sinew Pharma Inc.
Hepatic Failure
Study To Evaluate The Pharmacokinetics, Safety, And Tolerability Of Dimebon [Pf-01913539] In Subjects With Hepatic Impairment And Normal Hepatic Function
1. To compare the pharmacokinetics of Dimebon in subjects with mild and moderate hepatic impairment to subjects with normal hepatic function. 2.
- Trial name
- NCT00831532
- Testing
- Dimebon
- Where
- 2 sites in United States
- Volunteers
- 23 people, healthy volunteers welcome
- Sponsor
- Pfizer
Hepatic Encephalopathy, Minimal Hepatic Encephalopathy
A Study of MHE in Patients With Liver Diseases
The study analyzes the diagnostic efficacy of neurophysiological tests and blood biomarkers on MHE, predicts risk factors on the development of OHE and investigate the mortality of MHE in patients with cirrhosis and acute on…
- Conditions
- Hepatic Encephalopathy, Minimal Hepatic Encephalopathy, Overt Hepatic Encephalopathy
- Trial name
- NCT04058327
- Testing
- neurophysiological tests, blood biomarkers.
- Where
- China
- Volunteers
- 252 people, healthy volunteers welcome
- Sponsor
- Qin Ning
Liver Cirrhosis, Hepatic Encephalopathy
Electronic PHES vs Paper-based PHES for Hepatic Encephalopathy
This is a prospective, multicenter, randomized crossover diagnostic accuracy study. A total of 80 patients with liver cirrhosis will be enrolled and randomly assigned to two sequence groups at a 1:1 ratio.
- Conditions
- Liver Cirrhosis, Hepatic Encephalopathy, Minimal Hepatic Encephalopathy
- Trial name
- NCT07852416
- Testing
- Paper-based Psychometric Hepatic Encephalopathy Score (PHES), Electronic Psychometric Hepatic Encephalopathy Score (PHES)
- Where
- 2 sites in China
- Volunteers
- 80 people, healthy volunteers welcome
- Sponsor
- The First Affiliated Hospital with Nanjing Medical University
Liver Failure
Fecal Microbiota Transplantation for Liver Failure
To investigate the safety, adverse reactions and therapeutic effects of fecal microbiota transplantation on patients with liver failure;to investigate the effect of fecal microbiota transplantation on the intestinal microecology…
- Trial name
- NCT05170971
- Testing
- fecal microbiota transplantation
- Where
- China
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- Ningbo Medical Center Lihuili Hospital
Liver Transplant; Complications, Cirrhosis
Technology Enabled Strategies to Promote Treatment Adherence in Liver Transplant
Liver transplantation is increasingly performed for older adults with multiple comorbidities. Medication adherence is key to maintaining proper function of the transplanted liver and optimize health; however, adhering to…
- Conditions
- Liver Transplant; Complications, Cirrhosis, End Stage Liver DIsease, Medication Adherence
- Trial name
- TEST (NCT05260268)
- Testing
- TEST Intervention
- Where
- 3 sites in United States
- Volunteers
- 361 people, healthy volunteers welcome
- Sponsor
- University of Pennsylvania
Renal Failure, Hepatic Failure
The Role of Skin Microbiota in Hepatic or Renal Pruritus
Various neurotransmitters may share in the pathogenesis of hepatic and renal itching. Skin microbiota may share in the pathogenesis of pruritus.
- Conditions
- Renal Failure, Hepatic Failure, Pruritus
- Trial name
- NCT05604469
- Testing
- Isolation of skin microbiota
- Where
- Egypt
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- Zagazig University
Hepatic Encephalopathy, Minimal Hepatic Encephalopathy
A Prospective Cohort Study on the Epidemiological Investigation, Diagnosis, and Treatment of Hepatic Encephalopathy
Purpose Hepatic encephalopathy (HE) is a serious complication of liver cirrhosis that can cause memory loss, slow reaction, and even coma.
- Conditions
- Hepatic Encephalopathy, Minimal Hepatic Encephalopathy, Liver Cirrhosis
- Trial name
- NCT07612670
- Testing
- wechat mini-program
- Where
- China
- Volunteers
- 700 people, healthy volunteers welcome
- Sponsor
- The First Affiliated Hospital with Nanjing Medical University
Hepatic Encephalopathy
Cerebrovascular Reactivity in Hepatic Encephalopathy
It has been observed that patients with cirrhosis present a generalized state of vasoconstriction as an homeostatic response to splanchnic arteriolar vasodilatation.
- Trial name
- NCT01099293
- Where
- Mexico
- Volunteers
- 90 people, healthy volunteers welcome
- Sponsor
- Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran
Liver Diseases
Liver Diseases: Extracellular Vesicles as Biomarkers
Worldwide, cirrhosis is responsible for 2 million deaths per year. Hepatocellular carcinoma (HCC) accounts for 800,000 of these deaths and is the 3rd leading cause of cancer related death.
- Trial name
- LIVER-TRACK (NCT07185360)
- Testing
- blood sampling for volunteers, blood sampling for diabetics patients with F3/F4 fibrosis, blood sampling for patients with liver disease
- Where
- France
- Volunteers
- 845 people, healthy volunteers welcome
- Sponsor
- Assistance Publique - Hôpitaux de Paris